# Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

> **NCT00093990** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 457 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Tipifarnib;Zarnestra; R115777

## Key facts

- **NCT ID:** NCT00093990
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2016-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093990, "Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00093990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*